covalent KRASG12C inhibitor

in clinical development for KRASG12C+ cancers

from optimization of known starting point

J. Med. Chem., Apr. 6, 2020

Array / Mirati Therapeutics

MRTX849

April 2020’s molecule, the Mirati KRAS G12C inhibitor MRTX849, has been a hotly followed compound in development as it is the closest clinical KRAS inhibitor to the likely soon-to-be approved…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: